SCROLL DOWN FOR THE LATEST PRESS RELEASES AND TWEETS For media enquiries about any aspect of the work of the PMCPA please contact the Press Office via the switchboard: 020 7747 8880 Email us at email@example.com Sign up for eAlerts at the top of the page and follow us on Twitter @PMCPAUK
The PMCPA publishes certain Sanctions (advertisements, public reprimands and corrective statements) Press Releases and Case Reports.
In each case where a breach of the ABPI Code of Practice for the Pharmaceutical Industry is ruled, the company concerned must give an undertaking that the practice in question has ceased forthwith and that all possible steps have been taken to avoid a similar breach in the future. The undertaking must be accompanied by details of the action taken to implement the ruling. At the conclusion of a case, a detailed case report is also published.
Additional sanctions can also be imposed. These include:
- the carrying out by the PMCPA of an audit of a company’s procedures to comply with the Code. This can also be followed by a requirement that promotional material be submitted to the PMCPA for pre-vetting for a specified period
- requiring the company to take steps to recover items from those to whom they have been given
- requiring the company to issue a corrective statement
- a public reprimand
- suspension or expulsion from membership of the ABPI.
Where companies are ruled in breach of Clause 2 of the Code, and/or are required to issue a corrective statement and/or are the subject of a public reprimand, the PMCPA advertises brief details of the cases in the medical, nursing and pharmaceutical press, the advertisements are also published on this website.
When cases are considered under the Code they will first appear on this site as an ongoing case, limited information is provided which includes a brief summary and the status of the case. At the conclusion of any case, a case report is published summarising the details of the case, these appear as completed cases on this site. The transparency of cases is vital. Case reports are published for all cases which are within the scope of and considered under the Code, whether they are found to have breached the Code or not.
As mentioned above, in some cases a company may be required to issue a corrective statement or may be the subject of a public reprimand or advertisements in the medical and pharmaceutical press.
New vacancies at the PMCPA
20 October 2023read more
Novartis, Roche, Croma Pharma, Daiichi Sankyo, AstraZeneca and AbbVie named in advertisements for breaches of the ABPI Code
18 October 2023read more
Vacancies for independent members of the Code of Practice Appeal Board
09 August 2023read more
PMCPA Annual Report
01 August 2023read more
Vacancy for the position of Manager, PMCPA (12 Month FTC)
21 June 2023read more
Leo Pharma, AstraZeneca and Daiichi Sankyo have been named in advertisements for bringing discredit upon, and reducing confidence in, the pharmaceutical industry.
16 June 2023read more